According to a release issued by the National Organization for the Reform of Marijuana Laws, Epidiolex, a prescription medicine containing a standardized formulation of... DEA reclassifies plant-derived marijuana medicine

According to a release issued by the National Organization for the Reform of Marijuana Laws, Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified by the U.S. Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. Epidiolex is the first prescription drug derived from the marijuana plant.

The U.S. Food and Drug Administration had previously approved the product in June for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. It is the first botanically-derived medicine from cannabis to receive U.S. market approval.

A spokesperson for the DEA affirmed that the change is only specific to Epidiolex and does not amend the schedule I status of either whole-plant cannabis or CBD:

“As of right now, any other CBD product other than Epidiolex remains a Schedule I controlled substance, so it’s still illegal under federal law.” [Read more at News Leader]

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.




( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )